Drug intelligence / Profile preview

GEM-based Foam

Development stage: Preclinical
Lead developer: GEM-Biosciences
Modality: Small Molecules
Administration: Rectal

Overview

GEM-based Foam is a preclinical therapeutic candidate developed by GEM-Biosciences for the treatment of gastrointestinal and liver-related inflammatory diseases, including ulcerative colitis, proctitis, and pouchitis. The drug utilizes proprietary Gas-Entrapping Material (GEM) technology to stabilize and deliver carbon monoxide (CO) directly to the site of inflammation. Carbon monoxide acts as a signaling molecule with potent anti-inflammatory and cytoprotective properties. The formulation is designed for rectal instillation, allowing for localized delivery to the colon and rectum to minimize systemic exposure while maximizing therapeutic efficacy in inflammatory bowel disease (IBD) and related conditions.

Other names: GEM-CO foamgas-entrapping material foam

Targets

CO (Carbon monoxide)

Beyond the preview

Go deeper on GEM-based Foam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEM-based Foam.

Explore the full profile